ETHIC Act
- Sponsor
- Rep. Arrington, Jodey C. [R-TX-19]
- Committees
- Judiciary Committee (primary)
- Last action
- May 8, 2025
Bottom line
The bill aims to reduce the burden of "patent thickets" on generic drug and biosimilar manufacturers by restricting the number of related patents that can be litigated simultaneously, potentially leading to increased competition and lower drug prices.
What it actually does
This bill amends patent law to limit the number of patents that can be asserted in an infringement action against generic drug manufacturers or biosimilar producers. Specifically, it restricts a patent holder to asserting no more than one patent per defined "Patent Group" in such lawsuits, and prohibits additional actions from the same Patent Group against the same party. A "Patent Group" is defined by common ownership and the use of disclaimers under existing patent law.
Proponents argue
Proponents argue that this bill fosters competition in the pharmaceutical and biological product markets by making it easier for generic and biosimilar companies to challenge patents without facing an overwhelming number of lawsuits from a single patent holder. This could lead to lower drug prices, increased access to affordable medications, and a more efficient patent litigation system.
Opponents contend
Opponents, likely brand-name pharmaceutical companies, would contend that this bill undermines essential patent protections, disincentivizes innovation, and could lead to a decrease in research and development for new drugs and biological products. They might argue it unfairly limits their ability to defend their intellectual property, which is crucial for recouping significant R&D investments.
The bill is very short and can be read quickly, but understanding its full implications requires familiarity with complex patent law and pharmaceutical regulatory frameworks.
Section 2(a), amending Section 271(e) of title 35, United States Code
Restricting Patent Assertions in Drug and Biologic Infringement Actions
This provision limits a patent holder to asserting no more than one patent per "Patent Group" in an infringement lawsuit against companies seeking to produce generic drugs or biosimilars. It also prevents additional lawsuits from the same Patent Group against the same party. A "Patent Group" is defined as two or more commonly owned patents or applications that are linked by disclaimers under section 253 of title 35, U.S. Code, which are often used to extend patent protection.
Supporters argue
Supporters argue this provision directly tackles "patent thickets," where brand-name companies use a large number of overlapping patents to delay generic and biosimilar competition, thereby keeping drug prices high. By limiting assertions, it streamlines litigation and promotes timely market entry for affordable alternatives, benefiting patients and the healthcare system.
Critics contend
Opponents would contend that this provision weakens intellectual property rights, making it harder for innovators to protect their investments in research and development. They might argue that it could discourage the development of complex new drugs and biologics if the patent protection is perceived as insufficient to justify the substantial R&D costs.
Tradeoffs
This provision navigates the tension between promoting competition and lowering drug costs versus protecting intellectual property rights and incentivizing pharmaceutical innovation. It aims to prevent the strategic misuse of patent portfolios while maintaining a framework for legitimate patent enforcement.
Section 2(b)
Effective Date for Patent Assertion Limits
The amendment made by this Act will apply only to applications for generic drugs or biosimilar biological products that are submitted on or after the date the ETHIC Act is enacted. This means the new rules will not retroactively affect applications submitted before the bill becomes law, providing a clear transition period.